Search
SOLACI Congress
HomeFile

File

View Category
Coronary disease

Arterial Patency in Femoropopliteal Disease with Drug-Eluting Balloons

Follow-up of drug-coated balloon angioplasty in femoropopliteal disease in a real-world population. Using drug-releasing devices has decreased the...
solaci -
Learn More
Coronary disease

Should We Use Drug Coated Balloons in Patients with Multivessel Disease?

Recent studies have shown that a drug coated balloons (DCB) based approach resulted non inferior when compared...
solaci -
Learn More
Coronary disease

BIODEGRADE: Does Stent Design Affect Long-Term Clinical Results?

Recent studies have shown that drug-eluting stents with biodegradable polymer and ultrathin struts are safe and effective,...
solaci -
Learn More
Acute coronary syndromes

Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis

3 Year Clinical Outcome Analysis and Failure Predictors in the Use of Intracoronary Brachytherapy for Drug-Eluting Stent...
solaci -
Learn More
Acute coronary syndromes

Plaque Erosion with No Stenting in Acute Coronary Syndrome: Are There Event Predictors to Avoid This Strategy?

 Event predictors in patients with plaque erosion and no stenting. A third of all acute coronary syndrome (ACS)...
solaci -
Learn More
Acute coronary syndromes

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

 Monotherapy in patients with complex angioplasty: meta-analysis of 5 randomized studies.  Even though prolonged dual antiplatelet therapy (DAPT)...
solaci -
Learn More
Aorta

Uncomplicated Type B Aortic Dissection

Mortality Assessment, Interventions and Hospitalization in Patients with Uncomplicated Type B Aortic Dissection with TEVAR. Over 60% of...
solaci -
Learn More
Antiplatelet

Is Using Drug-Eluting Balloons and Single Antiplatlelet Therapy Safe for Patients at High Risk for Bleeding Who Undergo Percutaneous Coronary Intervention?

The safety and efficacy of drug-coated balloons (DCB) has been established for the treatment of in-stent restenosis...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy